Neonatal Drug Therapy Manual

MetroNIDAZOLE

Disclaimer: Official controlled document is the CHEO and Ottawa Hospital online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
Flagyl
Classification: 
Antibiotic
Original Date: 
January 1993
Revised Date: 
December 2025
Indications: 
  •  Infections due to susceptible anaerobic organisms
  • Definite Necrotizing Enterocolitis
Administration: 
  • IV intermittent infusion: over 30 -  60 minutes
Dosage: 

General Dosing:

CGA Loading Dose Maintenance Dose*
24 to < 34 weeks

15 mg/kg/dose once

7.5 mg/kg/dose Q12H
34 to 40 weeks  15 mg/kg/dose once 7.5 mg/kg/dose Q8H
> 40 weeks 15 mg/kg/dose once 10 mg/kg/dose Q8H

*initiate maintenance dosing 24 hours after the loading dose

Side Effects: 
  • GI: vomiting, diarrhea
  • GU: dark brown urine discolouration
  • Hematologic: mild transient leukopenia
  • Local: thrombophlebitis
Parameters to Monitor: 
  • WBC count
Reconstitution and Stability: 
  • Metronidazole 5 mg/mL (premix bag)  
Compatibility: 

- Solutions Compatible: D5W, 0.9% NaCl

- Y-site Compatible: acyclovir, dexmedetomidine, dopamine, fluconazole, heparin, hydromorphone, midazolam, milrinone, morphine, piperacillin/tazobactam, SMOF, TPN, vasopressin

Notes: 
  • Contains 28 mmol Na/g.
References: 
  • Dannelley JF, Martin EM, Chaaban H, Miler JL.  Review of Metronidazole Dosing in Preterm Neonates. Am J Perinatol, 2017 Jul; 34 (9): 833-38.
  • Randell RL, Balevic SJ, Greenberg RG, Cohen-Wolkowiez M, Smith MJ, Benjamin DK Jr, Bendel C, Bliss JM, Chaaban H, Chhabra R, Dammann CEL, Downey LC, Hornik CD, Hussain N, Laughon MM, Lavery A, Moya F, Saxonhouse M, Sokol GM, Trembath A, Weitkamp J-H, Hornik CP; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee. Metronidazole exposure-response and safety in infants. Antimicrob Agents Chemother. 2025 Nov 5;69(11):e0037725.
  • Cohen-Wolkowiez M, Sampson M, Bloom BT, Arrieta A, Wynn JL, Martz K, Harper B, Kearns GL, Capparelli EV, Siegel D, Benjamin DK Jr, Smith PB; Best Pharmaceuticals for Children Act–Pediatric Trials Network. Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants. Pediatr Infect Dis J. 2013 Sep;32(9):956-61.
  • Cohen-Wolkowiez M, Ouellet D, Smith PB, James LP, Ross A, Sullivan JE, Walsh MC, Zadell A, Newman N, White NR, Kashuba AD, Benjamin DK Jr. Population pharmacokinetics of metronidazole evaluated using scavenged samples from preterm infants. Antimicrob Agents Chemother. 2012 Apr;56(4):1828-37.
  • Taketomo CK, Hodding JH, Kraus DM. Pediatric Dosage Handbook 22nd Edition. Hudson: Lexi-Comp Inc; 2015
  • American Society on Health-System Pharmacists (ASHP). Handbook on Injectable Drugs. 19th Edition: Bethesda: ASHP 2017

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.